Verismo Therapeutics, a subsidiary of HLB Innovation, has secured the PACK-IT platform technology from Stanford University School of Medicine, which can generate KIR-CAR-T cells directly inside the body.


Verismo Secures In Vivo CAR-T Technology... "Overcoming the Limitations of Existing Therapies" View original image

According to Verismo on November 18, the licensing agreement will bring in next-generation CAR-T cell engineering technology developed by the research team led by Dr. Crystal Mackall, a professor of pediatrics and medicine at Stanford University School of Medicine and the founding director of the Stanford Cancer Cell Therapy Center.


Currently approved CAR-T therapies are produced ex vivo: T cells are collected from patients, genetically modified and expanded at a separate manufacturing facility, and then administered back to the patients after quality testing. This process typically takes several weeks, and its complex manufacturing procedures and high costs limit patient access.


In preclinical research presented by Professor Mackall's team at last year's American Association for Cancer Research (AACR) Annual Meeting, CAR-T cells generated using PACK-IT showed greater efficacy than those produced using conventional lentiviral methods. The researchers also confirmed that CD19-targeted CAR-T cells generated in vivo suppressed leukemia.


Verismo plans to integrate the technology into its next-generation multi-chain KIR-CAR platform and develop an off-the-shelf in vivo CAR-T therapy. By replacing the complex ex vivo manufacturing process with same-day in vivo delivery, the company aims to reduce treatment time and costs and improve patient access.



Brian Kim, CEO and co-founder of Verismo, said, "The KIR-CAR platform is a core technology designed to overcome the limitations of existing CAR-T therapies by minimizing off-target toxicity and inducing sustained antitumor effects. With the addition of PACK-IT technology, we will expand our development efforts into in vivo CAR-T therapies and work to provide more patients with faster, more affordable treatment options."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing